Shahin Akhondzadeh
Affiliations: | Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran |
Area:
schizophrenia, Purinergic ReceptorsGoogle:
"Shahin Akhondzadeh"Mean distance: 18.91 (cluster 56)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Tilaki EH, Hasanzadeh A, Shalbafan M, et al. (2023) Reboxetine Combination Therapy With Fluoxetine in Moderate to Severe Obsessive-Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial. Clinical Neuropharmacology. 46: 175-180 |
| Tilaki EH, Hasanzadeh A, Shalbafan M, et al. (2023) Reboxetine Combination Therapy With Fluoxetine in Moderate to Severe Obsessive-Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial. Clinical Neuropharmacology. 46: 175-180 |
| Ansari S, Sanjari Moghaddam H, Basti FA, et al. (2023) Efficacy and safety of celecoxib monotherapy for treatment of moderate depressive symptoms following COVID-19 infection: A randomized, double-blind, placebo-controlled trial. Journal of Psychosomatic Research. 174: 111471 |
| Nasiri M, Parmoon Z, Farahmand Y, et al. (2023) l-carnitine adjunct to risperidone for treatment of autism spectrum disorder-associated behaviors: a randomized, double-blind clinical trial. International Clinical Psychopharmacology |
| Nematizadeh M, Ghorbanzadeh H, Moghaddam HS, et al. (2023) L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial. Psychiatry and Clinical Neurosciences |
| Shamabadi A, Kafi F, Arab Bafrani M, et al. (2023) l-theanine adjunct to sertraline for major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial. Journal of Affective Disorders. 333: 38-43 |
| Shamabadi A, Ahmadzade A, Aqamolaei A, et al. (2022) Ketamine and Other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials. Iranian Journal of Psychiatry. 17: 320-340 |
| Ebrahimi P, Seyedmirzaei H, Moradi K, et al. (2022) Cilostazol as adjunctive therapy in treatment of children with autism spectrum disorders: a double-blind and placebo-controlled randomized trial. International Clinical Psychopharmacology |
| Abbasian F, Bagheri S, Moradi K, et al. (2022) Evidence for Anti-inflammatory Effects of Adalimumab in Treatment of Patients With Major Depressive Disorder: A Pilot, Randomized, Controlled Trial. Clinical Neuropharmacology. 45: 128-134 |
| Zandifar A, Badrfam R, Sanjari Moghaddam H, et al. (2022) Efficacy of Spironolactone as an Adjunctive Therapy to Risperidone to Improve Symptoms of Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled, Clinical Trial. Iranian Journal of Psychiatry. 17: 14-23 |